<DOC>
	<DOCNO>NCT03004391</DOCNO>
	<brief_summary>In 2015 Danish Health authority initiate major change national follow-up ( FU ) program ovarian cancer patient . The new FU program argues effect routine monitoring tumour marker CA125 . Now every patient need choose wish routine measurement CA 125 part follow-up program . Shared Decision Making ( SDM ) help health professional develop individualize care plan collaboration patient , state revise national FU program . Due complexity challenge within ovarian cancer care , evident area focus . SDM define approach clinician patient go phase decision-making process together share preference treatment reach agreement treatment choice . Clinicians information disease , test treatment , whereas patient hold information life circumstance , goal life , preference healthcare . SDM thereby offer way individualize recommendation , accord patient ' special need preference . SDM potential give patient high quality healthcare put patient center care . Decision aid ( DA ) tool provide information systematically describe advantage disadvantage specific intervention monitoring , help patient become involved decision making . Using evidence-based DA lead improvement knowledge , good understand screening , prevention treatment option , accurate perception risk patient . All participant fill demographic Decisional Conflict Scale questionnaire baseline . After present decision aid make choice CA125 , participant complete CollaboRATE Decisional Conflict Scale questionnaire deal confidence choice make level share decision making experience . Six month later Decision Regret Scale questionnaire complete reveal regret relation CA125 decision . For preliminary investigation applicability DA , 15-20 patient eligible study ask opinion .</brief_summary>
	<brief_title>Development Decision Aid Facilitate Ovarian Cancer Patient 's Choices Regarding Biomarker CA125</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients &gt; 18 year age Histologically confirm epithelial ovarian , fallopian tube serous primary peritoneal cancer Have complete first line treatment , complete remission . Manage read speak Danish Have recurrent disease first line treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Shared decision making</keyword>
	<keyword>Follow-up</keyword>
</DOC>